LncRNA MDRL Mitigates Atherosclerosis through miR-361/SQSTM1/NLRP3 Signaling

You, Long; Zheng, Yufeng; Yang, Jing; Hou, Qingzhi; Wang, Lianxia; Zhang, Yan; Zhao, Chunxia; Xie, Ruiqin

doi:10.1155/2022/5463505

Cited by 7 publications

(2 citation statements)

References 35 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lin et al reported the association between mitochondrial dynamic-related lncRNA (MDRL) and atherosclerosis in VSMCs [55]. They first demonstrated that MDRL is downregulated in atherosclerotic plaques, and overexpression of MDRL ameliorated the burden of plaques in the aortic roots of low-density lipoprotein receptor knockout (LDLR −/− ) mice.…”

Section: Atherosclerosismentioning

confidence: 99%

Noncoding RNAs as Key Regulators for Cardiac Development and Cardiovascular Diseases

Kawaguchi

Moukette

Hayasaka

et al. 2023

JCDD

View full text Add to dashboard Cite

Noncoding RNAs (ncRNAs) play fundamental roles in cardiac development and cardiovascular diseases (CVDs), which are a major cause of morbidity and mortality. With advances in RNA sequencing technology, the focus of recent research has transitioned from studies of specific candidates to whole transcriptome analyses. Thanks to these types of studies, new ncRNAs have been identified for their implication in cardiac development and CVDs. In this review, we briefly describe the classification of ncRNAs into microRNAs, long ncRNAs, and circular RNAs. We then discuss their critical roles in cardiac development and CVDs by citing the most up-to-date research articles. More specifically, we summarize the roles of ncRNAs in the formation of the heart tube and cardiac morphogenesis, cardiac mesoderm specification, and embryonic cardiomyocytes and cardiac progenitor cells. We also highlight ncRNAs that have recently emerged as key regulators in CVDs by focusing on six of them. We believe that this review concisely addresses perhaps not all but certainly the major aspects of current progress in ncRNA research in cardiac development and CVDs. Thus, this review would be beneficial for readers to obtain a recent picture of key ncRNAs and their mechanisms of action in cardiac development and CVDs.

show abstract

Section: Atherosclerosismentioning

confidence: 99%

Noncoding RNAs as Key Regulators for Cardiac Development and Cardiovascular Diseases

Kawaguchi

Moukette

Hayasaka

et al. 2023

JCDD

View full text Add to dashboard Cite

show abstract

“…Atherosclerosis (AS) is a chronic inflammatory artery disease that has emerged as a major public health concern around the world [ 1 , 2 ]. Endothelial cell dysfunction is defined by increased inflammatory gene expression or decreased diastolic and contractile function [ 3 ], whereas endothelial cell activation is characterized by increased inflammatory gene expression and permeability, both of which are thought to be major causes of AS [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Different roles of endothelial cell-derived fibronectin and plasma fibronectin in endothelial dysfunction

Luo,

JIAN

2023

Turkish Journal of Medical Sciences

View full text Add to dashboard Cite

Background/aim Atherosclerosis is significantly influenced by endothelial cell activation and dysfunction. Studies have demonstrated the substantial presence of fibronectin (Fn) within atherosclerotic plaques, promoting endothelial inflammation and activation. However, cellular Fn (cFn) secreted by various cell types, including endothelial cells and smooth muscle cells, and plasma Fn (pFn) produced by hepatocytes. They are distinct forms of Fn that differ in both structure and function. The specific contribution of different types of Fn in promoting endothelial cell activation and dysfunction remain uncertain. Therefore, this study aimed to investigate the respective roles of pFn and endothelial cell-derived Fn (Fn EC ) in promoting endothelial cell activation and dysfunction. Materials and methods Initially, endothelial cell injury was induced by exposing the cells to oxidized low-density lipoprotein (ox-LDL) and subsequently we generated a mutant strain of aortic endothelial cells with Fn knockdown (Fn EC-KD ). The impact of the Fn EC-KD arel the addition of pFn on the expression levels of inflammatory factors, vasoconstrictors, and diastolic factors were compared. Results The results showed that the Fn EC-KD significantly inhibited ox-LDL-induced intercellular adhesion molecule 1 (ICAM-1, p < 0.05), vascular cell adhesion molecule (VCAM-1, p < 0.05), and endothelin (p < 0.05) expression, and nuclear factor kappa-B (NFκB, p < 0.05) activation. These results implied that Fn EC-KD inhibited both endothelial cell activation and dysfunction. Surprisingly, the addition of pFn significantly inhibited the ox-LDL-induced ICAM-1 (p < 0.05), VCAM-1 (p < 0.05), and endothelin (p < 0.05) expression and NFκB (p < 0.05) activation. Implying that pFn inhibits endothelial cell activation and dysfunction. Additionally, the study revealed that ox-LDL stimulation enhanced the production of excessive nitric oxide, leading to severe endothelial cell damage. Conclusion Aortic Fn EC promotes endothelial cell activation and endothelial dysfunction, whereas pFn inhibits ox-LDL-induced endothelial cell activation and endothelial dysfunction.

show abstract

Top Five Stories of the Cellular Landscape and Therapies of Atherosclerosis: Current Knowledge and Future Perspectives

Pan,

Chen,

Yang

2023

CURR MED SCI

View full text Add to dashboard Cite

Atherosclerosis (AS) is characterized by impairment and apoptosis of endothelial cells, continuous systemic and focal inflammation and dysfunction of vascular smooth muscle cells, which is documented as the traditional cellular paradigm. However, the mechanisms appear much more complicated than we thought since a bulk of studies on efferocytosis, transdifferentiation and novel cell death forms such as ferroptosis, pyroptosis, and extracellular trap were reported. Discovery of novel pathological cellular landscapes provides a large number of therapeutic targets. On the other side, the unsatisfactory therapeutic effects of current treatment with lipid-lowering drugs as the cornerstone also restricts the efforts to reduce global AS burden. Stem cell- or nanoparticle-based strategies spurred a lot of attention due to the attractive therapeutic effects and minimized adverse effects. Given the complexity of pathological changes of AS, attempts to develop an almighty medicine based on single mechanisms could be theoretically challenging. In this review, the top stories in the cellular landscapes during the initiation and progression of AS and the therapies were summarized in an integrated perspective to facilitate efforts to develop a multi-targets strategy and fill the gap between mechanism research and clinical translation. The future challenges and improvements were also discussed.

show abstract

LncRNA MDRL Mitigates Atherosclerosis through miR-361/SQSTM1/NLRP3 Signaling

Cited by 7 publications

References 35 publications

Noncoding RNAs as Key Regulators for Cardiac Development and Cardiovascular Diseases

Noncoding RNAs as Key Regulators for Cardiac Development and Cardiovascular Diseases

Different roles of endothelial cell-derived fibronectin and plasma fibronectin in endothelial dysfunction

Top Five Stories of the Cellular Landscape and Therapies of Atherosclerosis: Current Knowledge and Future Perspectives

Contact Info

Product

Resources

About